We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance: Longer Diabetes Trials Needed to Evaluate Cardiac Risk
Guidance: Longer Diabetes Trials Needed to Evaluate Cardiac Risk
January 7, 2009
Sponsors of experimental Type 2 diabetes drugs approved for Phase II or III studies under an IND, including those already under way, should prepare for longer trials to better evaluate cardiovascular risk.